Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ARTV News 17 October 2025 - 16 December 2025

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is back on traders’ radars on December 16, 2025, after a sharp, high-volume move that has pushed the clinical-stage biotech into “crowded trade” territory—where catalysts, liquidity, and sentiment can matter as much as fundamentals. As of this morning, ARTV is trading around $6.30. That price level matters because it follows a session marked by unusually heavy volume and extreme intraday swings, and it arrives alongside fresh SEC disclosure of an insider transaction—two ingredients that often amplify attention in small- and mid-cap biotech. ARTV stock price today: the move that put Artiva back in the spotlight
16 December 2025
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments – from surging share price and volume to analyst projections of multi-fold upside – underscore the high stakes and high hopes riding on AlloNK’s success. For biotech investors and observers, ARTV will be a stock to watch closely in the coming months, as upcoming trial data and FDA feedback chart the next chapter for this promising yet still speculative biotech play. Latest Stock Price and Trend Analysis 247marketnews.com
17 October 2025
·

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Go toTop